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Abstract
Background: The b1-adrenergic receptor (ADRB1)
plays a pivotal role in mediating signal transduction
of the sympathetic-adrenal system, which is involved
in the regulation of cardiac output and peripheral
resistance. Our goal was to determine whether the
polymorphisms Arg389Gly (rs1801253) and Ser49Gly
(rs1801252) of the ADRB1 gene were associated with
essential hypertension in Chinese.
Methods: We tested our hypothesis in two independ-
ent case-control studies, one comprised 481 patients
with hypertension and 529 control subjects, and the
other study comprised 212 patients and 325 control
subjects. All subjects were genotyped for Arg389Gly
and Ser49Gly polymorphisms.
Results: The first study showed that the Arg389Arg
genotype of the ADRB1 gene was associated with risk
of hypertension wodds ratio (OR) 1.77, 95% confidence
interval (CI) 1.09–2.98; ps0.008x, and the association
was replicated in the second independent population
(OR 1.65, 95% CI 1.07–2.89, ps0.01). The patients
with the Arg389Arg genotype had significantly higher
diastolic blood pressure (DBP) than did those with
Arg389Gly genotype as well as those with Gly389Gly
genotype (100.29"11.01 mm Hg vs. 95.33"13.10
mm Hg and vs. 96.17"12.18 mm Hg, respectively,
ps0.01, ps0.02). The association was replicated in
the second study (103.7"13.3 mm Hg vs. 97.31"12.9
mm Hg and vs. 96.29"13.4 mm Hg, respectively,
ps0.03, ps0.02). Heart rate also showed an associ-
ation (in first study: 79.43"9.90 bpm vs. 74.87"
8.96 bpm, vs. 73.92"8.18 bpm, respectively, ps0.02,
ps0.014; in the second study: 81.12"8.99 bpm vs.
74.85"7.97 bpm and vs. 73.89"9.12 bpm, ps0.007,
ps0.006, respectively). No association was seen
between systolic blood pressure (SBP) and any of the
three genotypes at amino acid position 389 in hyper-
tensive patients, neither between the Ser49Gly poly-
morphisms and hypertension, nor between the
Ser49Gly genotypes and DBP and heart rate.
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Conclusions: The polymorphisms of the ADRB1 gene
were associated with essential hypertension. The
Arg389Gly polymorphism of the ADRB1 gene confers
higher risk for hypertension.
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Introduction
Essential hypertension (EH) is a multifactorial disease
with a substantial genetic component (1, 2). It has
been reported that the role of genetic factors respon-
sible for blood pressure is estimated as being up to
30%–50% (3). Blood pressure is determined by two
factors: cardiac output and peripheral resistance,
which are regulated by the sympathetic nervous sys-
tem (4). The b1-adrenergic receptor (ADRB1) plays a
pivotal role in mediating signal transduction in the
sympathetic-adrenal system.
The human ADRB1 is a member of the family of
seven-transmembrane G-protein-coupled receptors,
and expressed in cardiac myocytes (5). The ADRB1
gene was cloned in 1987, and localized to chromo-
some 10 (6). In the ADRB1 coding region, two single
nucleotide polymorphisms (SNPs) have been identi-
fied (7). The Arg389Gly polymorphism is located in
the intracellular cytoplasmic tail near the 7th trans-
membrane region of the receptor, which is a puta-
tive Gs-protein binding domain. The Arg389 variant
mediates higher isoproterenol-stimulated adenylate
cyclase activity than the Gly389 variant in vitro (8).
The Ser49Gly polymorphism is located in the extra-
cellular amino-terminal region of the receptor (Ser-to-
Gly substitution) (9). A previous study has shown that
the Gly49 ADRB1 displays more profound agonist-
promoted down-regulation compared with the Ser49
ADRB1 variant (10). In cells expressing Gly49 ADRB1,
both basal and agonist stimulated adenylyl cyclase
activities are also higher than in cells expressing the
Ser49 variant (Ser49 ADRB1) (11). These experimental
results suggest that polymorphism in the ADRB1
gene (Arg389Gly and Ser49Gly) might have important
biological significance in the pathogenic process of
hypertension.
The goal of the present study was to investigate
whether the functionally important Arg389Gly poly-
morphism or the Ser49Gly polymorphism of the
ADRB1 gene was associated with hypertension. The
results obtained from the first population were repli-
cated in another independent population of hyper-
tensive subjects.
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Materials and methods
Subjects
The subjects of the first study were comprised of outpatients
from a hospital in Shijiazhuang city, Hebei province, People’s
Republic of China. The subjects consisted of 481 patients
with mild and moderate EH, and age- and gender-matched
controls (529) from the same area. According to World
Health Organization (WHO) criteria (12), patients were
defined as being hypertensive if they had systolic blood
pressure (SBP) and/or diastolic blood pressure (DBP) G140/
90 mm Hg on three occasions within 2 months and not tak-
ing anti-hypertensive treatment, and/or if they had been
diagnosed as being hypertensive in the past and were cur-
rently receiving anti-hypertensivemedications. Patientswere
excluded if they had renal disease, secondary hypertension,
atrio-ventricular conduction block, chronic obstructive bron-
chitis, bronchial asthma, chronic myeloproliferative dis-
eases, diabetes, hypertrophy cardiomyopathy, valvular heart
diseases, pulmonary hypertension, coronary heart disease
or heart failure. Blood pressure was measured by the same
investigator using the right arm with a mercury sphygmo-
manometer and standard techniques after at least 5 min of
rest in a sitting position.
The controls were recruited from age- and gender-
matched healthy subjects from the same city. They had no
history or symptoms of cardiovascular diseases. All partici-
pants were of the Han ethnic group. Informed consent was
obtained from all individuals.
In the second study, the population was from a community
center in Beijing Fengtai District. The study population was
comprised of 212 cases with hypertension and 325 control
subjects and was recruited using the same criteria as the first
study. The study was approved by the Ethics Committee of
the Hebei Provincial People’s Hospital and the participating
hospital.
Determination of biochemical variables and clinical
data collection
Blood samples were collected following a 12-h overnight
fast. All samples were analyzed for serum sodium, potassi-
um, creatinine, uric acid, blood urea nitrogen (BUN), total
plasma cholesterol (TC), triglyceride (TG), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C) and blood glucose within 3 months using an
automated analyzer (Hitachi 7060, Hitachi, Tokyo, Japan). A
complete medical history was obtained from all subjects,
including family history of hypertension, diabetes mellitus,
and the following cardiovascular risk factors, alcohol intake,
cigarette smoking, family history of coronary heart disease
or stroke, weight, height, body mass index (BMI), SBP, and
DBP. BMI was calculated using the formula of weight (kg)/
height (m2). A complete clinical history was obtained from
all subjects.
Genotyping of Arg389Gly and Ser49Gly
Peripheral blood (10 mL) was collected into tubes containing
trisodium citrate (final concentration in blood, 0.026 mol/L),
and centrifuged at 3000 g for 10 min at room temperature.
The plasma and ‘‘buffy-coat’’ were separated and stored in
a 1.5-mL EP tube at –708C. All assays were performed in
duplicate. DNA was extracted from the ‘‘buffy-coat’’ as
described previously (13), and stored at –708C before use.
Single nucleotide polymorphism Arg389Gly was analyzed
by amplification of a 530-base pair (bp) sequence with prim-
ers: 59-CGC TCT GCT GGC TGC CCT TCT TCC -39 and 59-TGG
GCT TCG AGT TCA CCT GCT ATC-39 (6). The polymerase
chain reaction (PCR) products were digested with BcgI (New
England Biolabs, Beverly, MA, USA); only one band for the
Gly389Gly homozygote, two DNA fragments of 376 bp and
154 bp were obtained for the Arg389Arg homozygote on 3%
agarose gel and three bands for the Arg389Gly heterozygote.
The Ser49Gly polymorphism was amplified using PCR
with the following primers: 59-CCGGGCTTCTGGGGTGTTCC-
39 and 59-GGCGAGGTGATGGCGAGGTAGC-39 (6). The resul-
tant PCR products of 562 bp were digested with Eco0109I
(New England Biolabs, Beverly, MA, USA). Only one band
for the Ser49Gly homozygote, two DNA fragments of 342 bp
and 220 bp were obtained for the Gly49Gly homozygote
on 3% agarose gel, and three bands for the Ser49Gly
heterozygote.
The sequence was confirmed by bidirectional sequencing
of 200 samples with ABI Prism 3730 Genetic Analyzer
(Applied Biosystems Inc.) (14), and the reproducibility was
100%.
Data are expressed as mean"standard deviation (SD). The
x2-test was used for testing categorical variables, the
Hardy-Weinberg equilibrium of the polymorphisms, and
genotype/allele frequencies. Quantitative variables between
groups were tested with Student’s test. The association of
SNPs with hypertension was analyzed using multivariate
logistic regression. The analysis was adjusted for age, gen-
der, BMI, smoking, alcohol consumption, glucose, HDL-C,
LDL-C, TC, TG and family history of hypertension. A two-
tailed p-0.05 was considered significant. Statistical analysis
was performed with the SPSS 13.0 package. A SHEsis soft-
ware platform (http://analysis.bio-x.cn/myAnalysis.php) was
used to analyze pairwise linkage disequilibrium (LD) (15).
The D9 and r2 were used to indicate the strength of LD.
Results
Characteristics of the subjects
The characteristics of patients and control subjects
are shown in Table 1. The levels of SBP, DBP, TG,
glucose and LDL-C were significantly higher in hyper-
tensive patients than in controls. No differences in
BMI, TC or heart rate were found between cases and
controls.
Genotype distributions of Ser49Gly and Arg389Gly
polymorphisms
The distributions of Gly389Gly, Arg389Gly and
Arg389Arg genotypes of the ADRB1 polymorphism
are shown in Table 2. They were in agreement with
Hardy-Weinberg equilibrium for both cases and con-
trols. The frequency of the Arg389Arg genotype was
significantly higher in hypertensive patients than in
controls. The association remained after adjustment
for age, gender, and other conventional risk factors
with multiple logistic regression analysis in the two
independent populations (Table 2, Figure 1).
The distributions of Ser49Gly genotypes frequen-
cies are summarized in Table 2. They were in agree-
ment with Hardy-Weinberg equilibrium for both cases
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Table 1 Clinical characteristics.
Variables First population Second population
Hypertension (ns481) Controls (ns529) Hypertension (ns212) Controls (ns325)
Age, years 55.45"10.80 54.69"10.43 56.31"11.12 55.28"10.61
Gender, male (%) 53.56 50.81 54.14 52.36
BMI, kg/m2 25.09"2.63 24.80"2.63 26.17"2.49 22.98"2.18
SBP, mm Hg 158.44"18.67a 120.4"12.4 160.12"17.89a 117.4"11.3
DBP, mm Hg 97.3"12.1a 78.5"7.2 99.1"13.2a 76.9"8.1
HDL-C, mmol/L 1.36"0.20b 1.46"0.29 1.35"0.18b 1.48"0.31
LDL-C, mmol/L 2.98"0.54b 2.78"0.77 3.02"0.67a 2.67"0.59
TC, mmol/L 4.73"0.93 4.95"1.09 4.82"0.89 4.79"0.98
TG, mmol/L 1.68"0.42b 1.35"0.51 1.72"0.51b 1.34"0.49
Glucose, mmol/L 5.32"1.48b 4.74"1.25 5.51"1.39b 4.66"1.39
Heart rate, beats miny1 76.07"9.02 73.27"7.91 76.62"8.68 72.89"8.23
Drinking, % 23 21.6 24.2 20.9
Smoking, % 24.6 23.1 25.1 21.2
Family history of 30b 15.2 26b 13
hypertension, %
aHypertensive patients vs. controls p-0.01. bHypertensive patients vs. controls p-0.05. BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; TC, total plasma cholesterol; TG, triglyceride.
Table 2 Distribution of the ADRB1 Ser49Gly polymorphisms in hypertensive patients and controls.
Groups Arg389Gly genotype Ser49Gly genotype
Arg/Arg Arg/Gly Gly/Gly Gly/Gly Gly/Ser Ser/Ser
First population
Hypertensive patients, n (%) 249 (51.8)a 197 (40.9) 35 (7.3) 321 (66.8) 146 (30.2) 14 (3)
Controls, n (%) 245 (46.3) 232 (43.9) 52 (9.8) 360 (68.0) 156 (29.5) 13 (2.5)
Second population
Hypertensive patients, n (%) 112 (53)a 81 (38.2) 19 (8.8) 138 (64.9) 67 (31.6) 7 (3.5)
Controls, n (%) 149 (45.8) 143 (44.1) 33 (10.1) 218 (67.1) 93 (28.7) 14 (4.2)
x2-test vs. control or hypertensive patients. ap-0.05.
Figure 1 Association of the ADRB1 Arg389Gly polymorphism with hypertension.
The odds ratio (OR) of the Arg389Arg genotype in the first population was 1.77 w95% confidence interval (CI) 1.09–2.98;
ps0.008x. The OR in the second independent population was 1.65 w95% CI 1.07–2.89, ps0.01x. OR and 95% CI were calculated
using multivariate logistic regression analyses. Adjusted OR were stratified by age, gender, body mass index, systolic blood
pressure, diastolic blood pressure, glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyc-
eride; total plasma cholesterol; family history of hypertension.
and controls. No statistically significant differences in
Ser49Gly genotypes frequencies were found with the
x2-test in hypertensive patients and controls (Table 2).
Any association between the Ser49Gly polymorphism
and hypertension was not found in the two independ-
ent populations.
Arg389Gly and Ser49Gly polymorphism
and clinical phenotypes
In the first study population, 249 (51.8%) patients
were homozygous for the Arg389allele, 197 (40.9%)
patients were heterozygous, and 35 (7.3%) patients
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were homozygous for the Gly389 allele. In the second
study population, 53% were homozygous for
Arg389Arg, 38.2% were heterozygous for the
Arg389Gly, and 8.8% homozygous for Gly389Gly.
Hypertensive patients carrying Arg389Arg variants
had significantly increased DBP and heart rate by one-
way ANOVA analysis. However, no difference was
found in SBP among the three genotypes of
Arg389Gly in the two populations (Table 3).
No difference was identified in clinical variables
(including SBP, DBP and HR) among the three geno-
types of Ser49Gly in hypertensive patients in the two
populations using one-way ANOVA (Table 3).
Linkage disequilibrium analysis
LD was performed between the Arg389Gly and
Ser49Gly using the standard definition of D9 and r2.
We found that the two SNPs were not in LD with
D9s0.26 and r2s0.04, indicating that the two SNPs
were not in a same natural haplotype block.
Discussion
The present study found that the Arg389Gly polymor-
phism of ADRB1 is associated with hypertension in
Chinese. Hypertensive patients with Arg389Arg
variants had significantly increased DBP. This is the
first investigation to test the association between
Arg389Gly or Ser49Gly ADRB1 polymorphisms with
hypertension in two independent populations. This
finding is consistent with the results reported by
Bengtsson et al., where individuals homozygous for
the Arg389 allele of the ADRB1 gene were at
increased risk of developing hypertension (16). Shioji
et al. reported that the prevalence of the Gly389
ADRB1 variant was significantly lower in hypertensive
compared with normotensive patients, which also
supports our result (17). Karlsson reported that the
Ser49Gly ADRB1 polymorphism had no effect on bas-
al hemodynamics in hypertensive patients (18). How-
ever, some inconsistent results have been reported
showing that the prevalence of the Arg389Gly and the
Ser49Gly ADRB1 polymorphisms in hypertensive
patients was not different from that in normotensive
subjects from the same region (19). Several reasons
might explain the discrepancies between these stud-
ies. First, the frequencies of genotypes, alleles, haplo-
types and LD pattern may differ between various
ethnic groups. Second, the different prevalence and
clinical feature of hypertension in different ethnic
populations can affect the results of the association
study (20). Our study also found that patients with the
Arg389Arg genotype had a higher heart rate than
those that were either homozygous or heterozygous
for Gly389, suggesting that the receptor variant
Arg389Arg had higher sensitivity in response to cat-
echolamines. Homozygous subjects for the Arg389
allele showed an increase in response to stimulation
of the b1-adrenergic receptor by catecholamines.
In vitro studies have shown that the Arg389 variant
of the ADRB1 gene mediates an increased response
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to agonist stimulation compared with the Gly389
variant. This suggests that the Arg389Gly polymor-
phism is of functional importance. The Arg389 variant
exhibited slightly higher basal adenylyl cyclase activ-
ity than the Gly389 variant. In addition, isoprenaline-
induced adenylyl cyclase activation was about 3–4
times greater in Arg389 than in Gly389 ADRB1 cells.
This may be due to a reduction in the beta-AR-Gs
protein coupling for the Gly389 ADRB1 (7, 21). Similar
results have been obtained in cells expressing the
Arg389 ADRB1 or Gly389 ADRB1, where the maximal
increase in cyclic adenosine monophosphate caused
by isoprenaline was significantly larger in Arg389
than in Gly389 ADRB1 cells (22). The increased in vivo
activity of the Arg389 variant of ADRB1 could be
expected to lead to higher cardiac output, and could
therefore explain the association between the Arg389
allele and hypertension in our study. This may also
partially explain our results that Arg389Gly polymor-
phism conferred a higher risk of hypertension.
The strength of our study is that the result was com-
pletely replicated in another independent population,
remote from the first population. The subjects in the
present study were all of Han ethnic group to control
for population stratification. In addition, we selected
hypertensive patients with a relatively early age at
onset, and control subjects without a family history of
hypertension to avoid selection bias of patients and
controls. However, some limitations must be consid-
ered. The sample size can affect the consequences of
an association study. Therefore, our results need to
be confirmed in a larger sample of individuals.
In conclusion, our findings suggest that the
Arg389Arg genotype of the ADRB1 gene confers an
increased risk for development of hypertension.
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